India's First Drug EMR Could Set Off Litigation Wave, Industry Warns
The grant of India's first exclusive marketing right (EMR) to Swiss drugmaker Novartis for its leukemia medicine Gilvec (imatinib mesylate) could set off a wave of patent litigation, the Economic Times...To view the full article, register now.
Already a subscriber? Click here to view full article